KRAS and neoplasm: Furthermore, KRAS is responsible of an immunosuppressive tumor microenvironment within mutated tumors in a PD-L1 dependent manner [24, 25], and the effect of MRTX849 was diminished when CT26 KRASG12C+/+ were grown in T cell deficient nude mice [26].